The R&D wing at Sanofi-Aventis is turning to China to find new ways to fight cancer and rheumatoid arthritis. The French pharma giant wants to forge a half dozen research partnerships with scientists in state-funded labs and Chinese universities. Analysts note that while China has become a key player for low cost- -and sometimes high risk--drug manufacturing, Chinese officials have been investing huge sums to build up its drug research operations. China intends to become a leader in drug research, and the world's drug developers are playing close attention to the opportunities that trend will offer them.
"I think the amount of people with a master's in biology in China is now bigger than the number of people with a master's in biology in the U.S.," Marc Cluzel (photo), head of Sanofi's R&D, tells the Wall Street Journal. "The number of people with a Ph.D. in biology in the U.S. is still higher than in China, but it's getting closer and closer. And they are doing some good fundamental science."
- read the report in the Wall Street Journal
Sanofi makes moves in China. Report
Sanofi signs stem cell pact in China. Report
Sanofi to build vaccine plant in China. Report
China pushes drug development as R&D soars. Report